Drug intelligence / Profile preview

YAM80

Development stage: Unknown
Lead developer: Yoshino Neurology Clinic
Administration: Oral

Overview

YAM80 is an investigational drug developed by Yoshino Neurology Clinic for the treatment of amyotrophic lateral sclerosis (ALS). It has been evaluated in a Phase 2 clinical trial as an oral therapy for ALS, with dosing ranging from 2 to 6 mg once daily over a period of 24 weeks. The precise mechanism of action, molecular target, and chemical class of YAM80 have not been disclosed in public sources. Its development status remains pending, and there is no evidence that it has reached regulatory approval or commercialization[1][2][3].

Beyond the preview

Go deeper on YAM80.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YAM80.

Explore the full profile